A novel circular RNA therapy expressing a long-acting FGF21 analog protein reversed obesity, insulin resistance, and steatosis in mouse models

被引：0
|
作者：
Cao, Rui [1 ]
Wan, Haitao [1 ]
Zeng, Jing [1 ]
Gao, Lu [2 ]
机构：
[1] Therorna Shanghai Co Ltd, Shanghai, Peoples R China
[2] Therorna Inc, Beijing, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-223
引用
收藏
页码：S573 / S573
页数：1
相关论文
共 12 条
  • [1] Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
    Hale, Clarence
    Chen, Michelle M.
    Stanislaus, Shanaka
    Chinookoswong, Narumol
    Hager, Todd
    Wang, Minghan
    Veniant, Murielle M.
    Xu, Jing
    ENDOCRINOLOGY, 2012, 153 (01) : 69 - 80
  • [2] Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity
    Kim, Daejin
    Lee, Jongsoo
    Bae, InHwan
    Kim, Minyoung
    Huh, Youngho
    Choi, Jaehyuk
    Bae, Sungmin
    Choi, In Young
    Kim, Ha Hyung
    Kim, Dae Kyong
    BIOLOGICALS, 2021, 69 : 49 - 58
  • [3] A novel long-acting FGF21 analogue significantly improves liver steatosis and halters progression of fibrosis in pre-clinical models of NASH
    Henriksson, Emma
    Norlin, Jenny
    Galsgaard, Elisabeth D.
    Kirk, Rikke K.
    Rakipovski, Gunaj
    Andersen, Birgitte
    HEPATOLOGY, 2017, 66 : 1061A - 1061A
  • [4] A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway
    Bao, Lichen
    Yin, Jun
    Gao, Wen
    Wang, Qun
    Yao, Wenbing
    Gao, Xiangdong
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (16) : 3379 - 3393
  • [5] Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice
    Bartesaghi, Stefano
    Wallenius, Kristina
    Hovdal, Daniel
    Liljeblad, Mathias
    Wallin, Simonetta
    Dekker, Niek
    Barlind, Louise
    Davies, Nigel
    Seeliger, Frank
    Winzell, Maria Sorhede
    Patel, Sima
    Theisen, Matt
    Brito, Luis
    Bergenhem, Nils
    Andersson, Shalini
    Peng, Xiao-Rong
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 28 : 500 - 513
  • [6] YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models
    Kim, Jun Hwan
    Hong, Han Na
    Choi, Hyun Ho
    Kim, Dohoon
    Kim, Tae Wang
    Lim, Seyoung
    Seo, Minji
    Ju, Mi Kyeong
    Park, Ju-Young
    Choi, Byung Hyun
    Tolbol, Kirstine S.
    Feigh, Michael
    Vrang, Niels
    Kim, Jong Gyun
    Nam, Su Youn
    HEPATOLOGY, 2016, 64 (06) : 1136A - 1137A
  • [7] CVX-343, a Long-Acting FGF21 CovX-Body, Demonstrates Prolonged Anti-Diabetic Efficacy in Diabetic Mouse Models
    Huang, Jie
    Rolzin, Paul
    Osothprarop, Trina F.
    Ishino, Tetsuya
    Wiese, Joe
    Retting, Kelsey
    Del Rosario, Joselyn
    Li, Lingna
    Vu, Calvin
    Matin, Marla J.
    Ainekulu, Zemeda W.
    Kinhikar, Arvind
    Palanki, Moorthy
    Huyghe, Bernard
    Violand, Bernard N.
    Finn, Rory F.
    Woodnutt, Gary
    Lappe, Rodney W.
    Levin, Nancy
    DIABETES, 2011, 60 : A285 - A285
  • [8] Sustained Glucagon Effect on Blood Glucose and Improvements of Insulin Resistance Mediated by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models
    Choi, Jaehyuk
    Lee, Seon Myeong
    Kim, Jung Kuk
    Lee, Jongsoo
    Kim, Young Hoon
    Choi, In Young
    DIABETES, 2019, 68
  • [9] YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis
    Kim, Dohoon
    Kim, Junhwan
    Kim, Tae Wang
    Hong, Han
    Choi, Hyun
    Yang, Ji-Eun
    Jeong, Da-Na
    Ju, Mi Kyeong
    Seo, Minji
    Kim, Su Kyung
    Park, Ju-Young
    Choi, Byung Hyun
    Kim, Han-Joo
    Ahn, Kyoung Kyu
    Kim, Jong-Gyun
    Bedossa, Pierre
    Ratziu, Vlad
    Oh, Se-Woong
    Choi, Soongyu
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E793 - E793
  • [10] YH25724, a novel long-acting GLP-1/FGF21 dual agonist provides potent and sustained glycaemic control, body weight loss and lipid profile improvement in animal models
    Hong, H. N.
    Kim, J. H.
    Choi, H. H.
    Kim, D.
    Lim, S.
    Seo, M.
    Ju, M. K.
    Park, J. Y.
    Choi, B. H.
    Kim, J. G.
    Nam, S. Y.
    DIABETOLOGIA, 2016, 59 : S58 - S58
12